Cleerly ISCHEMIA vs EchoSolv AS
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, including the likelihood of vessel-level ischemia and detailed plaque characterization, derived from CCTA scans. This tool is ideal for personalized diagnosis and treatment planning, offering insights into stenosis severity and 3D coronary artery models.
View Cleerly ISCHEMIA →Choose EchoSolv AS if…
Choose EchoSolv AS if you need an ultra-fast, AI-powered clinical decision support tool to accurately identify patients at high risk for severe aortic stenosis from existing echocardiogram measurements. This platform is best suited for streamlining workflows, prioritizing studies for closer review, and providing consistent, measurement-based severe AS probability and guideline checks.
View EchoSolv AS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | EchoSolv AS |
|---|---|---|
| Pricing | Contact for details | Unknown |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Cloud-based |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS emphasizes seamless integration into existing PACS workflows without requiring EMR integration, coupled with ultra-fast risk detection (under 3 seconds) and measurement-based AI, which simplifies data input. Cleerly ISCHEMIA, while web-based, involves data transfer via a proxy, potentially adding a minor layer of complexity to the user experience. EchoSolv AS also claims a 24.1% reduction in review time.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA offers a more comprehensive assessment of coronary artery disease by analyzing CCTA scans for non-invasive FFR estimation, vessel-level ischemia likelihood, and detailed coronary plaque characterization (volume, type, location). It has demonstrated higher diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE) in clinical trials. While EchoSolv AS is highly accurate for severe aortic stenosis, Cleerly's broader diagnostic scope and prognostic capabilities provide a more holistic view of heart health.
Pricing & Value
EchoSolv ASNeither tool provides transparent upfront pricing, requiring direct contact. However, EchoSolv AS offers more specific details regarding its reimbursement strategy, including an identified miscellaneous CPT code (93799) with an expected per-use reimbursement rate of US$100 to US$150, and anticipates a Category III CPT code. Cleerly ISCHEMIA is billable under established CPT codes (75580 and 75577), but specific reimbursement details are less transparent, stating that commercial payment will vary.
Enterprise Readiness
EchoSolv ASBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, establishing a strong foundation. EchoSolv AS explicitly highlights its design to fit existing workflows by integrating with PACS without requiring EMR integration, which streamlines enterprise deployment. Additionally, EchoSolv AS provides a SOC 2 Type II report and HIPAA audit program, further demonstrating its commitment to enterprise-grade security and compliance.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA's AI-enabled CCTA analysis for non-invasive fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization (volume, type, location) represents a significant advancement in non-invasive cardiac diagnostics. This moves beyond simple stenosis assessment to provide detailed physiological and anatomical insights with prognostic utility for MACE events. While EchoSolv AS's measurement-based AI for severe aortic stenosis is innovative, Cleerly's broader, multi-faceted approach to understanding coronary artery disease pushes the boundaries of non-invasive assessment further.
Support & Docs
EchoSolv ASEchoSolv AS provides more explicit details about its available documentation and resources, including a clinician user manual, SOC 2 Type II Report, HIPAA Audit Program, Privacy Policy, and Terms of Service. Cleerly ISCHEMIA offers general support and billing guidelines, but less specific information about comprehensive documentation for users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | EchoSolv AS |
|---|---|---|
| Name | Cleerly ISCHEMIA | EchoSolv AS |
| Company | Cleerly | Echo IQ |
| Description | FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows. |
| Primary Modality Analyzed | CCTA scans | Echocardiograms (numerical measurements, not images) |
| Key Feature 1 | AI-enabled CCTA analysis | AI-powered clinical decision support for severe aortic stenosis probability |
| Key Feature 2 | Non-invasive fractional flow reserve (FFR) estimation | Consistent severe AS probability and guideline check from measurements |
| Key Feature 3 | Vessel-level ischemia likelihood determination | Second reader support to help prioritize studies for closer review |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and EchoSolv AS.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or EchoSolv AS
Backers
Who funded each tool's parent company.